TUCSON, Ariz., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first U.S. and Canadian commercially-approved total artificial heart, today announced that it is not aware of any undisclosed material change in the Company’s operations or financial condition, that would account for the recent volatility in its stock price. The Company remains focused on executing its strategic and operational ...

Strong commercial momentum driven by higher product sales – Total revenue and $19.5 million IPO proceeds support expansion and innovation in artificial heart technology - TUSCON, Ariz., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first U.S. and Canadian commercially-approved total artificial heart, announced financial results for the quarter and six months ended June 30, 2025. In early ...

Appointments strengthen Picard’s Board with proven expertise in capital markets and global MedTech leadershipTUCSON, Ariz., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first U.S. and Canadian commercially-approved total artificial heart, today announced the appointment of two new members that will serve on its Board of Directors, Sam Van and George Ye. Both were appointed following the ...

TUCSON, Ariz., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), today announced that it closed its initial public offering of 4,250,000 shares of common stock, par value $0.0001 per share (the “Common Stock”) at $4.00 per share (the “Offering”). The Company has granted the underwriters an option, within 30 days from the closing date of the Offering, to purchase up to an additional 637,500 shares of Common Stock the public offering price, less underwri ...

Core Viewpoint - Picard Medical, Inc. has announced the pricing of its initial public offering (IPO), aiming to raise $17 million through the sale of 4,250,000 shares at $4.00 per share, with trading expected to commence on August 29, 2025 under the ticker symbol "PMI" [1][3]. Group 1: Offering Details - The IPO consists of 4,250,000 shares priced at $4.00 each, totaling gross proceeds of $17 million before expenses [1]. - Underwriters have an option to purchase an additional 637,500 shares within 30 days to cover over-allotments [1]. - The offering is being conducted on a firm commitment basis, with WestPark Capital, Inc. as the Lead Manager and Sole Bookrunner [2]. Group 2: Use of Proceeds - Proceeds from the IPO will support market expansion in China through a joint venture, fund research and development for new products, and enhance sales and marketing capabilities [3]. - The funds will also be used to repay debt and cover general operational expenses and working capital [3]. Group 3: Company Background - Picard Medical, Inc. is the parent company of SynCardia Systems, LLC, which manufactures the SynCardia Total Artificial Heart (STAH), the only FDA and Health Canada approved total artificial heart [6]. - The STAH is the most widely used artificial heart globally, with over 2,100 implants performed in 27 countries [6].